The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

The holidays are fast approaching along with cooler weather and various respiratory illnesses. Here's when to get your ...

Getting the one-dose RSV vaccine is one of the easiest ways to do so ... year from RSV and the state of Oklahoma saw a ...

Cassandra Archer, MD, FACP, FAAP, is director of community health services at the Cayuga County Health Department. For more ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

RESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back.